Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
For all your needs in CD7 CAR-T cell development, Creative Biolabs is the ultimate answer. Our comprehensive range of products and services ensures a complete solution for our clients. With our team of skilled professionals, we provide assistance with CAR design and construction as well as T cell engineering, ensuring that we fulfill your requirements successfully.
CD7, a cell membrane glycoprotein weighing 40 kDa, serves as a surface receptor. CD7, which is a member of the immunoglobulin supergene family, has the potential to be an effective target for CART. This is primarily due to its extensive expression in nearly all T-cell malignancies.
Fig.1 Timeline of CD7 target research.1
The CAR expression test involves a series of procedures that assess the presence and quantity of chimeric antigen receptors on immune cells. At Creative Biolabs, our unconjugated CD7, biotinylated CD7, fluorescent-labeled CD7, and custom cells with CD7 overexpression bind specifically to the scFv region of the CAR molecule, allowing for sensitive and accurate detection of anti-CD7 CAR expression. The results of the CAR expression test provide valuable information on the success of the genetic modification process and the efficiency of chimeric antigen receptor expression on the immune cells.
Fig.2 Surface expression of CD7 CAR in lentivirus-transduced T cells.2
CD7 CAR-T Cytokine Release Test
We provide CD7 CAR-T cytokine release test, aimed at assessing the cytokine release associated with CD7 CAR-T therapy. Our cytokine release test services employ advanced techniques, such as bead-based multiplex assays and flow cytometry, for the measurement of important cytokines, including IL-6, IL-8, IL-10, and IFNγ. Through precise cytokine measurement, we can evaluate the effectiveness of CAR-T treatment in targeting specific cancers and its overall impact on the immune system.
Fig.3 Changes in cytokines and temperature within the first month after infusion of CD7 CAR T-cells.3
CD7 CAR-T In Vitro Cytotoxicity Assay
Studies have demonstrated that the presence of CD7+ AML blasts can be significantly reduced in the CD7 CAR-T group. Creative Biolabs is pleased to access the cytotoxic activity of anti-CD7 CAR-T cells, facilitating our clients' research.
Fig.4 The primary CD7+ R/R-AML blasts exhibit cytotoxicity due to the presence of CD7 CAR.2
CD7 CAR-T Cell Therapy Animal Models
We will develop a suitable xenograft model to examine the effects of CD7 CAR-T cells in vivo.
Fig.5 mouse model construction and CAR-T-cell.2
We provide various in vivo assays to evaluate the killing capability and proliferation potential of the CD7 CAR-T cells.
Fig.6 The CD7 CAR-T cells show incredible efficacy against leukemia in a mouse model.2
Toxicity Evaluation of CD7 CAR-T
We provide tumor lysis analysis, on-target/off-tumor toxicologic effect analysis, tumorigenicity study, and other custom analysis for toxicity evaluation, monitoring for any signs of toxicity or adverse reactions.
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-1122-LX736 | Anti-CD7 (X11X338) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X338 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-1122-LX737 | Anti-CD7 (X11X339) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 | Human | X11X339 | Humanized | scFv-CD28-OX40-CD3ζ | Lentiviral vector | T cell | ||
| XS-0123-ZP287 | Anti-CD7 (RFT2) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | RFT2 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP288 | Anti-CD7 (CHT2) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | CHT2 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP530 | Anti-CD7 (CB-P21) h(scFv-CD3ε) TRuC, pCDTRC1 | Mouse | CB-P21 | Rat | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP704 | Anti-CD7 (TH-69) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | TH-69 | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP833 | Anti-CD7 (3A1e) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | 3A1e | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP834 | Anti-CD7 (m3A1e) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | m3A1e | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0123-ZP835 | Anti-CD7 (m3A1f) h(scFv-CD3ε) TRuC, pCDTRC1 | Human | m3A1f | Mouse | scFv-CD3ε | Lentiviral vector | T cell | ||
| XS-0323-ZP287 | Anti-CD7 (RFT2 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | RFT2 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP288 | Anti-CD7 (CHT2 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | CHT2 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP530 | Anti-CD7 (CB-P21 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Mouse | CB-P21 | Rat | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP704 | Anti-CD7 (TH-69 scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | TH-69 | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP833 | Anti-CD7 (3A1e scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | 3A1e | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP834 | Anti-CD7 (m3A1e scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | m3A1e | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-ZP835 | Anti-CD7 (m3A1f scFv-CD28TM-CD79β) CBCR(CAR-B), pCDCAR1 | Human | m3A1f | Mouse | scFv-CD28TM-CD79β | Lentiviral vector | T cell | CAR-B Vector | |
| XS-0323-LX140 | Anti-CD7 VHH(X3XH140) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH140 | VHH-CD28-41BB-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX878 | Anti-CD7 VHH(X3XH140) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH140 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX879 | Anti-CD7 VHH(X3XH141) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH141 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0323-LX880 | Anti-CD7 VHH(X3XH142) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector | Human | X3XH142 | VHH-CD28-OX40-CD3ζ | Lentiviral vector | T cell | CAR-T | ||
| XS-0823-LX22 | Anti-hCD7 (MAB) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | MAB | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
